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Summary SHetA2 is a small molecule flexible heteroarotinoid
(Flex-Het) with promising cancer prevention and therapeutic
activity. Extensive preclinical testing documented lack of
SHetA2 toxicity at doses 25 to 150 fold above effective doses.
Knowledge of the SHetA2 molecular target(s) that mediate(s)
the mechanism of SHetA2 action is critical to appropriate design
of clinical trials and improved analogs. The aim of this studywas
to develop a method to identify SHetA2 binding proteins in
cancer cells. A knownmetabolite of SHetA2 that has a hydroxyl
group available for attachment was synthesized and conjugat-
ed to a linker for attachment to a magnetic microsphere.
SHetA2-conjugated magnetic microspheres and unconjugated
magnetic microspheres were separately incubated with ali-
quots of a whole cell protein extract from the A2780 human
ovarian cancer cell line. After washing away non-specifically
bound proteins with the protein extraction buffer, SHetA2-
binding proteins were eluted with an excess of free SHetA2. In
two independent experiments, an SDS gel band of about
72 kDa was present at differential levels in wells of eluent
from SHetA2-microspheres in comparison to wells of eluent
from unconjugated microspheres. Mass spectrometry analysis
of the bands (QStar) and straight eluents (Orbitrap) identified
mortalin (HSPA9) to be present in the eluent from SHetA2-
microspheres and not in eluent from unconjugated micro-
spheres. Co-immunoprecipitation experiments demonstrated
that SHetA2 interfered with mortalin binding to p53 and p66
Src homologous-collagen homologue (p66shc) inside cancer
cells. Mortalin and SHetA2 conflictingly regulate the same
molecules involved in mitochondria-mediated intrinsic apo-
ptosis. The results validate the power of this protocol for
revealing drug targets.
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Abbreviations
CHOP CAAT/enhancer binding protein homologous
protein
FBS fetal bovine serum
Flex-Het flexible heteroarotinoid
FOXO3A forkhead box O3A
FT-MS Fourier transform mass spectrometry
HSPA heat shock protein A
IR infrared
MIPS monoisotopic precursor selection
NF-κB nuclear factor-κB
NMR nuclear magnetic resonance
NOAEL no observed adverse effect level
p66shc p66 Src homologous-collagen homologue
PTLC preparative thin layer chromatography
PVDS polyvinylidene difluoride
SAR structure activity relationship
SDS sodium dodecyl sulfate-polyacrylamide
SHetA2 sulfur heteroarotinoid A2
STAT3 signal transducer and activator of transcription 3
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Introduction
Advancement of investigational new drugs to clinical trials
requires detailed knowledge of the pharmacokinetics, metabo-
lism and toxicity to document that the compound has sufficient
pharmaceutical qualities for clinical application. Knowledge of
the mechanism can be used to select the appropriate patient
population and to design improved analogs. Pre-clinical testing
for our lead compound, a flexible heteroarotinoid (Flex-Het)
called Sulfur Het A2 (SHetA2, NSC721689) demonstrated
reasonable pharmacokinetics and lack of mutagenicity, carci-
nogenicity, teratogenicity and toxicity [1–5]. SHetA2 has a
wide therapeutic window as indicated by the No Observed
Adverse Effect Level (NOAEL) of >1,500 mg/kg/day identi-
fied in the 28 day dog toxicity model in comparison to the
ability of 10 to 60mg/kg/day to inhibit xenograft tumor growth
[5–8]. This lack of in vivo toxicity, along with oral bioavail-
ability and documented inhibition of colorectal tumorigenesis
in the APCmin/+ mouse model at 30 mg/kg given 5 days per
week, make SHetA2 an ideal candidate for a cancer prevention
drug [9]. SHetA2 sensitization of resistant cells to death recep-
tor activating ligands offers promise for advancement of
SHetA2 toward clinical trials as combination therapy with
death receptor activating antibodies that are currently in clinical
trials [10, 11]. Mechanistic studies identified that SHetA2 in-
duces G1 cell cycle arrest through reduction of cyclin D1;
induces intrinsic apoptosis through direct effects on mitochon-
dria associated with reduction of Bcl-2; enhances death receptor
activation of the extrinsic apoptosis pathway through repression
of nuclear factor κB (NF-κB) and upregulation of the CAAT/
enhancer binding protein homologous protein (CHOP) tran-
scription factor; and induces autophagy and endoplasmic retic-
ulum stress, however the direct mediators of these events
remain to be elucidated [7, 12–14].
The mechanism of SHetA2 is independent of the nuclear
retinoid receptors and retinoid toxicities, despite the emer-
gence of this compound from a series of structure activity
relationship (SAR) studies of retinoic acid receptor-active
Hets [3, 6, 15, 16]. SHetA2 was derived from a Het backbone
that was shown to have 1000-fold decreased in vivo toxicity in
comparison to the parent arotinoid structure while retaining
the ability to induce retinoid biological effects [6, 17]. The
increased flexibility of the Flex-Hets was conferred by
substituting the more-rigid two-atom linker with a more-
flexible, three-atom urea or thiourea linker [16]. The Flex-
Hets differ from the more conformationally-restricted
heteroarotinoids in that they act independently of the retinoic
acid receptors and are potent inducers of apoptosis in cancer
cells while not harming normal cells [3, 7, 10, 13, 16, 18]. The
potent and differential apoptosis-inducing activity and lack of
retinoid and other toxicities of SHetA2 offer a dramatic im-
provement in the therapeutic ratio over receptor active Hets.
The purpose of this project was to identify SHetA2-binding
proteins that may be responsible for mediating the mechanism
by which SHetA2 kills ovarian cancer cells.
A variety of approaches have been used for target identifi-
cation including direct biochemical methods, genetic interac-
tions, and computational inference. Mass spectrometry analy-
sis of drug binding proteins isolated by affinity chromatogra-
phy is currently the most powerful and frequently-used tech-
nology; however, a generic workflow for this procedure has
not been established due to the wide variation in the types of
drugs and the affinity and expression levels of their targets
[19]. The primary limitation of affinity chromatography is the
need to derivatize the drug in order to attach it to a scaffold,
because the derivative has high risk for losing the bioactivity
of the parent compound [20]. Linkers between the drug and
scaffold may be needed to avoid interference of the scaffold
with protein binding to the attached drug. In this study, a
known metabolite of SHetA2 was synthesized, which permit-
ted attachment to a linker designed in such a way that allowed
conjugation to a magnetic microsphere with a physical sepa-
ration between the drug and microsphere. Identification of a
SHetA2-binding protein using this affinity chromatography
approach was validated by identification of the same protein
in two types of mass spectrometry analyses and demonstration
that treatment of cells with SHetA2 interferes with target
protein binding to client proteins.
Materials and methods
Chemistry
In order to attach compound SHetA2 [1] to a solid support
while retaining the majority of the structure intact for protein
binding, the known metabolite 2 , which has a hydroxyl group
available for attachment, was synthesized as described [21]
(Structures of 1 and 2 are shown in Fig. 1). The SHetA2
metabolite 2 was then further modified as shown in Fig. 1.
Amino-dPEG4 acid was purchased from Quanta Biodesign
Limited, Powell, OH 43065, and used as received. Tetrahy-
drofuran was dried over potassium hydroxide pellets and
distilled from lithium aluminium hydride prior to use. Dichlo-
romethane was used from a freshly opened bottle. All reac-
tions were run under dry nitrogen in oven-dried glassware.
The reaction was monitored by thin layer chromatography
(TLC) on silica gel GF plates (Analtech No 21521). Purifi-
cation was performed using preparative thin layer chroma-
tography (PTLC) on a 20-cm×20-cm silica gel GF plate
(Analtech No 02015). Band elution for both methods was
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monitored using a hand-held UV lamp. The infrared (IR)
spectrum was run as a thin film on sodium chloride disks.
1H and 13C nuclear magnetic resonance (NMR) spectra were
measured in deuteriochloroform at 300 MHz and 75 MHz,
respectively, and were referenced to internal tetramethylsilane;
coupling constants (J) were reported in Hz. The ultraviolet–
visible (UV–vis) spectrum was collected for the sample
using a Varian Cary 5000 spectrophotometer. The mass
spectrum was collected for the sample using a Shimadzu
LC-MS instrument.
Fig. 1 Synthesis scheme for
SHetA2 conjugated magnetic
microspheres
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A 25-mL, three-necked, round-bottomed flask, equipped
with a reflux condenser and a magnetic stirrer was charged
with 100 mg (0.24 mmol) of metabolite 2 and 5 mL of
tetrahydrofuran. The solution was cooled to −40 °C, 29 mg
(0.24 mmol) of 4-(dimethylamino)pyridine was added. The
mixture was stirred for 5 min to dissolve the solid. To the
resulting yellow solution was added dropwise a solution of
48 mg (0.239 mmol) of 4-nitrophenyl chloroformate in
1 mL of tetrahydrofuran, and the reaction mixture was
allowed to stir for 30 min. At this time, TLC eluted with
ether:hexane (4:1) confirmed that the reaction was complete
(and formed 3) .
A solution of exactly 63 mg (0.24 mmol) of amino-dPEG
4-acid in 3 mL of dichloromethane was carefully added to the
above reaction mixture containing 3 at −40 °C over a period
of 10 min. The reaction mixture was then slowly allowed to
warm to room temperature over a period of 1 h. The reaction
mixture then was stirred for 20 min, and concentrated under
vacuum. Purification was achieved by PTLC eluted with 98:2
chloroform:methanol. After one elution, the product was
washed from the silica gel using ethyl acetate followed by
chloroform:methanol (95:5) to give 33 mg (20 %) of conju-
gate 4 as a pale yellow liquid. LCMS: (M+) 732 (Na+ adduct),
418; IR: 3375, 1740, 1640, 1592, 1515, 1475, 1335,
1110 cm−1; 1H NMR: 8.94 (s, 1 H), 8.76 (s, 1 H), 8.19 (d,
J =9.0 Hz, 2 H), 7.85 (obscured m, 1 H), 7.84 (d, J =9.0 Hz,
2 H), 7.45 (s, 1 H), 7.13 (d, J =8.2 Hz, 1 H), 5.46 (brt, J =ca
6.2 Hz, l H), 4.53 and 4.42 (2 AB patterns, J =11.0 Hz, 1 H),
3.76 (t, J =5.5 Hz, 2 H), 3.63 (m, 13 H), 3.40 (m, 2 H), 3.22
(m, 2 H), 2.60 (t, J =5.5 Hz, 2 H), 2.36 (d, J =14.2 Hz, 1 H),
1.83 (d, J =14.2 Hz, 1 H), 1.43 (s, 6 H), 1.40 (s, 3 H); UV–vis
(H3COH): max=285 nm (ε=1752) and 335 nm (ε=1456).
The 13C NMR experiment could not be carried out due to the
instability of the product. The product decomposed rapidly at
20 °C. Thus, the polyether was attached to the microspheres
without further purification.
Only a small quantity of conjugate 4 was obtained, and it
was transferred in dry ice to SoluLink (San Diego, CA).
Compound 4 was converted to compound 5 by a proprietary
method of SoluLink who provided a mass spectrum of the
compound as MW - Na+984, the primary m/z occurring at
884.20. Compound 5 was reacted with the magnetic micro-
spheres through an amide linkage. This led to conjugate 6
attached to the NanoLink Amino-Magnetic Microspheres
which were utilized to identify SHetA2 binding proteins.
Isolation of SHetA2 binding proteins
Protein extracts of the A2780 human ovarian cancer cell
line grown to 90 % confluency in 10 cm plates were
isolated using m-PER-PPI (m-PER solution [Thermo
Scientific] containing a protease inhibitor cocktail [Ac-
tive Motif] and a phosphatase inhibitor cocktail [Active
Motif]) and stored at −80 °C until use. The protein
concentration of the extracts was measured with the
BCA Protein Assay (Thermo Scientific). SHetA2-
conjugated NanoLink Amino-Magnetic Microspheres 6
were pelleted with a magnet for 2 min, and the super-
natant was removed. The pellet was washed once in
100 μL PBS and re-suspended in 100 μL of m-PER-
PPI. Unconjugated NanoLink Amino-Magnetic Micro-
spheres were manipulated under the same conditions in
parallel as a negative control. The general experimental
procedure is as follows with specific modifications de-
tailed in the subsequent paragraphs and Table 1. Equal
volumes of the SHetA2- and unconjugated-microsphere
suspensions were pelleted and re-suspended in A2780
protein extract and incubated. The microspheres were
pelleted with a magnet and washed one to three times
with m-PER-PPI at a volume equal to the incubation
volume. Bound proteins were then eluted with excess
free SHetA2 in m-PER-PPI, followed by removal of the
Table 1 Experimental Variables Used in Optimization
Protein/SHetA2 ratio Protein/Beads Ratio Incubation Conditions W Eluent Conditions Result
1 1360:1
6.8 mg: 5 μg
1:1
100 μL:100 μL




1.8 mg: 2.5 μg
1:1
50 μL:50 μL
37 °C, 30 min→ rt, 5 min 1 1 mM SHetA2
37 °C, 30 min
72 kDa specific banda
3 104:1
2.6 mg: 25 μg
1:100
50 μL:500 μL




10 mg: 13.75 μg
1:1.375
200 μL:275 μL
rt, 5 min→ 37 °C, 25 min 2 1 mM SHetA2
37 °C, 30 min
Differential 72 kDa bandb
a Proteins in silver stain-detected band could not be detected with Coomassie Blue or QStar, but proteins in free eluent could be detected with Orbitrap
b Band and eluent were successfully evaluated byMass Spec using QStar and Orbitrap, respectively. Specific band was present at a higher level than the
non-specific band in Coomassie stained SDS-gel
W = Number of washes, Beads = Microspheres
Bolded rows were used in Mass Spectrometry Analyses
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microspheres with a magnet. Aliquots of the washes and
eluents of the SHetA2- and unconjugated microspheres
were electrophoresed into 2-D SDS-PAGE gels. Four
repeats of the experiment were performed in efforts to
optimize differential bands observed in the SDS gel
wells corresponding to SHetA2-microspheres in compar-
ison to unconjugated microspheres.
In experiment 1, 100 μL of A2780 protein extract (6.8 mg
total) was mixed with a volume of 100 μL of SHetA2 micro-
spheres (containing approximately 5 μg or 12.45 nM
SHetA2) from the starting solution and incubated at room
temperature in the dark with agitation for 30 min. After 3
washes, bound proteins were eluted by incubating the micro-
spheres in 10 μM SHetA2 for 10 min with agitation in the
dark. Differential bands in the lanes corresponding to SHetA2
eluents from the SHetA2- and unconjugated microspheres
could not be visualized upon staining the SDS-PAGE gel with
Coomassie Blue.
Experiment 2 was designed to reduce the non-specific
binding in SDS-gel bands corresponding to unconjugated
microspheres by decreasing the amount of protein added and
to increase the specific binding in SDS-gel bands correspond-
ing to SHetA2-microspheres by increasing the incubation
temperature. Because a limited amount of microspheres was
available, both parameters were altered simultaneously. In
experiment 2, 50 μL of A2780 protein extract (1.8 mg) was
incubated with the SHetA2- or unconjugated magnetic micro-
spheres at 37 °C for 30 min in the dark without agitation,
followed by 5min of slow agitation at room temperature in the
dark. After one wash, bound proteins were eluted by incubat-
ing the microspheres with 1 mM SHetA2 in 20 μL of m-PER-
PPI for 30 min at 37 °C in the dark. Again no differential
bands were observed between the lanes corresponding to the
SHetA2- and unconjugatedmicrospheres eluents when the gel
was stained with Coomassi blue; however, a differential band
was observed upon staining of a repeat gel with the Plus One
DNA Silver Staining Kit (Amersham Biosciences) (Fig. 2a).
Experiment 3 was designed to increase the yield of this
specific band to levels that could be evaluated by mass spec-
trometry. Based on the presumption that the SHetA2 attached
to the microspheres was the limiting factor, the ratio of protein
to microspheres was altered to 1:100 by using a volume of
50 μL of A2780 protein extract containing 2.6 mg of protein
and incubating with 500 μL of unconjugated microspheres or
SHetA2-microspheres (25 μg or 62.25 nM SHetA2). The
extract was incubated and eluted as described for experiment
2; however, the levels of proteins present in the SDS-PAGE
gel lanes corresponding to SHetA2- and unconjugated micro-
spheres were too filled with non-specific binding proteins to
reveal a differential band.
Experiment 4 was designed to increase the yield by in-
creasing the amount of protein added and to reduce the non-
specific background binding by increasing the number of
washes. Thus, 275 μL of SHetA2-microspheres (13.75 μg
or 34.24 nM SHetA2) or unconjugated-microspheres were
mixed with 200 μL of A2780 protein extract (approximately
Fig. 2 SDS Gels. a Silver-
stained SDS-gel of aliquots of the
indicated washes and eluents
from experiment 2. b Coomassie
Blue-stained SDS-gel of SDS-G
of aliquots of the indicated
washes and eluents from
experiment 4. The arrow
indicates the location in the dried
gel where bands were excised
from the last two lanes for QStar
Mass Spectrometry Analysis.
Beads = Microspheres
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10 μg), agitated for 5 min in the dark at room temperature and
then incubated without agitation at 37 °C for 25 min in the
dark. Two washes with 300 μL of m-PER-PPI were per-
formed, followed by an elution step with 30 μL of 1 mM
SHetA2 in m-PER-PPI for 5 min at 37 °C. A differential band
was discerned between the lanes corresponding to the
SHetA2- and unconjugated microspheres upon Coomassie
blue staining of the SDS-PAGE gel; however, the non-
specific binding was very high (Fig. 2b).
Efforts to regenerate and re-use the SHetA2-microspheres
were unsuccessful. The specific bands in experiments 2 and 4
were evaluated by QStar Mass spectrometry and frozen ali-
quots of the eluents were thawed and evaluated by Orbitrap
Mass spectrometry.
Mass spectrometry analysis of bands excised
from SDS-PAGE gels
Identification of proteins that bind to the SHetA2 affinity resin
was determined by a standard proteomics analysis as briefly
described below. The protein bands were excised and cut into
small pieces and destained with 5 mM sodium thiosulfate/
15 mM potassium ferricyanide in water. After rinsing with
25 mM ammonium bicarbonate in 50 % acetonitrile, the
proteins in the gel were reduced in 55 mM tris[2-
carboxylethyl]phosphine in 25 mM ammonium bicarbonate
at 60 °C for 10 min, followed by alkylation in 100 mM
iodoacetoamide/25 mM ammonium bicarbonate at room tem-
perature for 60 min. After washing the alkylation buffer, the gel
pieces were washed in 50 % acetonitrile, followed by 100 %
acetonitrile. In-gel tryptic digestion was conducted by adding
100 ng of trypsin (Sequencing Grade Modified Trypsin;
Promega, Madison, WI) in 10 μL of 25 mM ammonium bicar-
bonate. The gel pieces were allowed to swell, and an additional
25 μL of 25 mM ammonium bicarbonate was added to sub-
merge the gel pieces. The digestion reaction was incubated at
30 °C for 16 hrs. Twenty-five microliters of 1 % trifluoroacetic
acid was added to stop the digestion reaction, and the tryptic
peptides were extracted into 50 % acetonitrile/0.5 %
trifluoroacetic acid. The extract was evaporated by a SpeedVac
concentrator (Thermo Electron Corporation, Waltham, MA). All
water used was an ultra-pure grade. A Dionex UltiMate 3000
HPLC interfaced to an ABI Sciex QStar Elite Hybrid Quadru-
pole TOF mass spectrometer was used to analyze the tryptic
digests by peptide mass fingerprinting. MASCOT (Matrix Sci-
ence, Boston, MA) analysis of the MS/MS data against NCBInr
20100405 identified three candidates that show Probability
Based MOWSE Score higher than 41 (p<0.05); gi|6470150
(Homo sapiens BiP protein; MOWSE Score, 1202),
gi|5729877 (Homo sapiens heat shock cognate 71 kDa protein
isoform 1;MOWSEScore, 1030), and gi|292059 (Homo sapiens
MTHSP75; MOWSE Score, 423).
Shotgun-mass spectrometry analysis
Aliquots of eluents from the SHetA2-microspheres and uncon-
jugated microspheres were submitted for mass spectrometry
analysis without electrophoresing them into gels. MS-grade sol-
vents were from Burdick and Jackson, or Baker. Sequencing
grade trypsin was from Promega. Other solutions were the
highest grade available from Sigma-Aldrich. Samples were dis-
solved in 8M urea, 100 mM Tris–HCl pH=8.5 at RT, 5 mM
tris(2-carboxyethyl)phosphine, and reduced at room temperature
for 20 min. After incubation, 1/20th volume of 200 mM
iodoacetamide was added. The alkylation was allowed to pro-
ceed for 15 min in the dark at room temperature, after which the
samples were diluted with four volumes of 100 mM TrisHCl
pH 8.5 and digested with 4 μg/mL trypsin overnight at 37 °C.
Digested samples were acidified with 1 % formic acid, and
purified by tip-based C18 chromatography (OMIX tips from
Agilent). Samples were analyzed on a hybrid LTQ-OrbitrapXL
mass spectrometer (Thermo Fisher Scientific) coupled to a New
Objectives PV-550 nanoelectrospray ion source and an Eksigent
NanoLC-2D chromatography system.
Peptides were analyzed by trapping on a 2.5 cm pre-
column, followed by analytical separation on a 15–20 cm
75 μm ID fused silica column, both packed with Magic C18
AQ (Bruker). Columns were terminated with an integral fused
silica emitter prepared in house. Peptides were eluted using a
5–40 % ACN/0.1 % formic acid gradient performed over
116 min at a flow rate of 250–300 nL/min. For each full-
range Fourier transform mass spectrometry (FT-MS) scan
(nominal resolution of 60,000), the six most intense ions were
analyzed via data-dependent MS/MS in the linear ion trap
using dynamic exclusion for 150% of the observed chromato-
graphic peak width. MS/MS settings used a trigger threshold
of 8,000 counts, monoisotopic precursor selection (MIPS),
and rejection of parent ions that had unassigned charge states
or were previously identified as contaminants. Centroided ion
masses were extracted using the extract_msn.exe utility from
Bioworks 3.3.1 and were used for database searching with
MASCOT v2.2.04 (Matrix Science) and X Tandem
v2007.01.01.1 (www.thegpm.org).
Searches utilized a local database of human sequences, as
well as sequences for 114 common adventitious laboratory
contaminants. Trypsinolytic parent ions were searched with a
parent ion tolerance of 10 ppm, and fragment ion masses were
searched with a mass tolerance of 0.8 Da. Variable modifications
included modification of cysteine by iodoacetamide or acrylam-
ide, oxidation of methionine, N-terminal peptide cyclization via
pyroglutamate or S-carbamoylmethylcysteine, and N-terminal
protein modification by formylation or acetylation.
Scaffold (Version 3, Proteome Software Inc., Portland, OR)
was used to validate MS/MS based peptide and protein identi-
fications. Peptide identifications were accepted if they could be
established at greater than 95 % probability as specified by the
Invest New Drugs (2014) 32:412–423 417
Peptide Prophet algorithm [22]. Protein identifications were
accepted if they could be established at greater than 99.0 %
probability and contained at least 2 identified peptides. Protein
probabilities were assigned by the Protein Prophet algorithm
[23]. Proteins that contained similar peptides and could not be
differentiated based on MS/MS analysis alone were grouped to
satisfy the principles of parsimony. A t-test was performed to
determine significant differences in proteins identified in the
eluents from SHetA2-microspheres in comparison to the elu-
ents from unconjugated microspheres. P values of less than
0.05 were considered to be statistically significant.
Cell culture and co-immunoprecipation experiments
The A2780 human ovarian cancer cell line (gift of Michael
Birrer, Harvard Medical School, Boston, MA) was cultured in
RPMI 1640 tissue culture medium supplemented with 10 %
fetal bovine serum (FBS), antibiotic/antimycotic, 1 nM sodi-
um pyruvate and 1 mM HEPES buffer. Whole cell protein
extracts were prepared from cultures treated with SHetA2 or
DMSO for various times using M-PER Mammalian Protein
Extraction Reagent (Thermo Scientific) or Triton×100 lysis
buffer consisting of 1 % Triton×100, 10 mM Tris pH 7.4,
5 mM EDTA pH 8.0, and 50 mM NaCl. Cells were incubated
and agitated by pipette or vortex every 5 min for 30 min. After
incubation, samples were spun down for 3 min at 10,000 g to
remove debris. Cell lysates were centrifuged to remove debris
for 5 min at 3,000 g using a 1:100 ratio of anti-p66shc
antibody (Santa Cruz, Cat # sc-967), anti-p53 antibody (Santa
Cruz, Cat # sc-126) or anti-mortalin antibody (Cell signaling
Cat # 3593) to lysate was added to each lysate immediately
and incubated at 4 °C overnight. The next day, cells were
incubated with Protein G-PLUS Agarose microspheres (Santa
Cruz) for 1 hr. Microspheres were then washed 3 times with
1 mL of 10 % NP-40/Tris pH 8.0 buffer and centrifuged at 3,
000 ×g for 4 min. Twenty microliters of SDS loading buffer
was then added to each sample, and the solution was boiled
for 5 min before being electrophoresed into a 12–15% sodium
dodecyl sulfate-polyacrylamide (SDS) gel electrophoresis,
transferred to a polyvinylidene difluoride (PVDF) membrane,
blocked in 5 % milk for 1 hr at room temperature, and then
immunoblotted with the desired primary antibody (anti-
mortalin antibody (Cell signaling Cat # 3593), anti-p53 anti-
body (Santa Cruz, Cat # sc-126) or anti-p66shc antibody
(Santa Cruz, Cat # sc-967) and then incubated overnight at
4 °C. The membranes were then washed 3 times with 10 mL
of PBS-Tween 20 (0.1 %), incubated with the appropriate
HRP-conjugated secondary antibody for 30 min at room
temperature and twashed 3 times with 10 mL of PBS-Tween
20 (0.1 %). Finally, specifically bound antibody was detected
using Western Blotting Luminol Reagent (Santa Cruz Bio-
technology) and exposure to X-Ray negative film.
Results
Identification of mortalin as an SHetA2-binding protein
To identify SHetA2 binding proteins, whole cell protein ex-
tracts isolated from the human A2780 ovarian cancer cell line
were incubated with NanoLink Amino-Magnetic Micro-
spheres conjugated to SHetA2. Unconjugated NanoLink
Amino-Magnetic Microspheres microspheres were used as a
control for non-specific binding. Solutions obtained through
washing the microspheres and eluting with excess SHetA2
were evaluated on SDS-PAGE gels. Conditions were modi-
fied in 4 independent experiments to optimize the specificity
and yield of proteins that bound to the SHetA2 microspheres
(Table 1). In the second experiment, a band of approximately
75 kDa was observed in the lane corresponding to the SHetA2
microsphere eluent and not in the lane corresponding to the
unconjugated microsphere eluent in a silver-stained SDS-
PAGE gel (Fig. 2a). The amount of protein present in the gel
however was insufficient for detection by the less-sensitive
Coomassie blue stain or QTrap mass spectrometry. By in-
creasing the microsphere to protein extract ratio and the num-
ber of washing steps, conditions were optimized to enable a
sufficient amount of protein differentially bound to the
SHetA2-microspheres compared to the unconjugated micro-
spheres that could be detected in an SDS-gel stained with
Coomassie blue (Fig. 2b). The areas of the dried gels for
experiments 2 and 4 corresponding to the differential
75 kDa band in the lanes corresponding to the SHetA2- and
unconjugated microsphere eluents were excised and subjected
to QStar mass spectrometry analysis. Although no proteins
could be detected in the bands from experiment 2, three
related heat shock protein A (HSPA) family members,
HSPA5, HSPA8 and HSPA9/mortalin, were identified to be
present in the band from the SHetA2-microspheres and not in
the band from the unconjugated-microspheres from experi-
ment 4 (Table 2).
To further validate the identification of these proteins,
aliquots of the eluents from the SHetA2- and unconjugated
microspheres from experiments 2 and 4 were evaluated by
“Shotgun” Orbitrap Mass spectrometry analysis. Twenty-five
individual proteins were identified to be present at significant-
ly different levels in the SHetA2-microsphere eluent com-
pared to the unconjugated-microsphere eluent in experiment
2 as determined by a t -test with p values below 0.05 being
considered significant (Table 3). Among these proteins, all
three HSPA5, HSPA8 and mortalin proteins, which were
identified in the previous QStar analysis, also were found to
be differentially present in the eluent from the SHetA2-
microspheres in comparison to the eluent from the unconju-
gated microspheres. Because experiment 4 had a much higher
background of non-specifically bound proteins, it was not
surprising that a much higher number (224) of individual
418 Invest New Drugs (2014) 32:412–423
proteins, were identified to be differentially present by using
the identical analysis procedure (Supplemental Table 1).
Among these proteins, mortalin, (with a p value of 0.00031
in Supplemental Table 1) was among the significant proteins
in both experiments 2 and 4, while HSPA5 and HSPA8 were
found to be significant in experiment 2, but had p-values
slightly above 0.05 in experiment 4 (listed at the bottom of
Supplemental Table 1). Thus, in two independent experiments
evaluated by two different proteomics approaches, mortalin
was identified to be specifically bound by SHetA2.
Table 3 Orbitrap analysis of SHetA2-microsphere eluent from experiment 2
Identified Protein Accession # MS p-value
1 Heterogeneous nuclear ribonucleoprotein G IPI00304692 42 kDa 0.00007
2 Uncharacterized protein IPI01021093 (+4) 33 kDa 0.00015
3 Endoplasmin IPI00027230 92 kDa 0.00015
4 ATP synthase subunit beta, mitochondrial IPI00303476 (+1) 57 kDa 0.00063
5 Insulin-like growth factor 2 mRNA-binding protein 1 IPI00008557 63 kDa 0.00078
6 30 kDa protein IPI00964648 (+8) 30 kDa 0.0015
7 Keratin, type I cytoskeletal 17 IPI00450768 48 kDa 0.0033
8 Nucleolin IPI00604620 77 kDa 0.0043
9 ATP synthase subunit alpha, mitochondrial IPI00440493 60 kDa 0.0052
10 Isoform B1 of Heterogeneous nuclear ribonucleoproteins A2/B1 IPI00396378 37 kDa 0.0061
11 cDNA FLJ55072, highly similar to Succinate dehydrogenase
(ubiquinone) flavoprotein subunit, mitochondrial
IPI00964764 67 kDa 0.0065
12 Isoform 3 of Heterogeneous nuclear ribonucleoprotein K IPI00807545 (+2) 49 kDa 0.0072
13 Heat shock protein HSP 90-beta IPI00414676 83 kDa 0.008
14 cDNA FLJ57283, highly similar to Actin, cytoplasmic 2 IPI00930226 (+3) 40 kDa 0.0084
15 Keratin, type I cytoskeletal 16 IPI00217963 51 kDa 0.0092
16 Peroxiredoxin-1 IPI00000874 (+1) 22 kDa 0.016
17 X-ray repair cross-complementing protein 6 IPI00644712 (+2) 70 kDa 0.016
18 Glyceraldehyde-3-phosphate dehydrogenase IPI00219018 (+2) 36 kDa 0.016
19 Isoform 1 of Polyadenylate-binding protein 1 IPI00008524 (+2) 71 kDa 0.019
20 Putative cytochrome b-c1 complex subunit Rieske-like protein 1 IPI00889196 (+1) 31 kDa 0.019
21 Vimentin IPI00418471 54 kDa 0.021
22 HSPA5/78 kDa glucose-regulated protein IPI00003362 72 kDa 0.023
23 Isoform 2 of Heterogeneous nuclear ribonucleoprotein A/B IPI00334587 (+4) 36 kDa 0.025
24 mortalin/Stress-70 protein, mitochondrial IPI00007765 (+1) 74 kDa 0.034
25 HSPA8/Isoform 1 of Heat shock cognate 71 kDa protein IPI00003865 (+1) 71 kDa 0.042








2 gi|5729877 1030 71082.81 628.0486 HSPA8: Hsc70, 2410008N15Rik, Heat Shock Cognate 71-KDA, Heat
Shock Cognate 8, HS7C, HSC54, HSC71, HSC73, HSP/C70, HSP70,
HSP71, HSP73, Hsp 8, HSPA10, LAP1, MGC102007, MGC106514,
MGC114311, MGC118485, MGC128130, MGC131511, MGC29929,
NIP71
3 gi|292059 423 74019.46 409.2786 mortalin: Mortalin, Mitochondrial stress-70, Glucose Regulated Protein 75,
GRP-75, 74 kDa, CSA, Hsc74, Hsp74, Hsp74a, Mortalina, mortalinB,
MGC4500,, MOT, Mot1, MOT2, Mthsp70, MTHSP75, PBP74, Stress-70
1 gi|6470150 1202 71002.07 312.8802 HSPA 5:Glucose Regulated Protein 78, GRP78, BiP, 78 kDa, AL022860,
AU019543, BIP, D2Wsu141e, D2Wsu17e, FLJ26106,, HEAT SHOCK
70KDA PROTEIN5, Hsce70, HSP70-5, Immunoglobulin heavy chain
binding, mBiP, MIF2, SEZ-7
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Validation of SHetA2 effects on mortalin
Mortalin is a molecular chaperone that binds client proteins
and supports their functional configuration and intracellular
localization [24]. To determine if SHetA2 interferes with
mortalin binding to client proteins in situ, the ability of
mortalin protein to be co-immunoprecipitated with its client
proteins was evaluated in protein extracts from the A2780 and
SK-OV-3 human ovarian cancer cell lines treated with
SHetA2 or control solvent for 4 hrs. Western blot analysis of
co-immunoprecipitates of protein extracts from both cell lines
demonstrated that an antibody to the mortalin client protein
called p66shc can pull down mortalin protein in the untreated
controls, but not in the SHetA2-treated cultures, indicating
that SHetA2 disrupted the interaction of these two proteins
inside the cell (Fig. 3a). Another mortalin client protein, p53,
was found to co-immunoprecipitate with the anti-mortalin
specific antibody in untreated control A2780 cultures, but
not in the SHetA2-treated cultures indicating that SHetA2
disrupts the interaction of these two proteins inside cells also
(Fig. 3b). To further confirm SHetA2 disruption of this inter-
a c t i o n , t h e A2780 p r o t e i n ex t r a c t s we r e co -
immunoprecipitated with an anti-p53 specific antibody.
Western blot analysis confirmed that mortalin was co-
immunoprecipitated with p53 in the control cultures, but not
in the SHetA2-treated cultures (Fig. 3c). The SK-OV-3 cell
line was not evaluated for mortalin/p53 interactions, because
this cell line does not express p53. To verify that this effect
was not due to a decrease in mortalin levels potentially caused
by SHetA2 treatment, protein extracts from A2780 and SK-
OV-3 cultures treated with SHetA2 or control solvent over a
range of treatment times were evaluated by Western blot,
which demonstrated similar levels of mortalin regardless of
the treatment time (Fig. 3d).
Discussion
This work has demonstrated that SHetA2 conjugated mag-
netic microspheres in concert with mass spectrometry ap-
proaches can be used to identify SHetA2 binding proteins.
In our review of the literature to this date, there is no other
report of using drug conjugated microspheres to identify a
drug binding protein. The validity of the identified mortalin
protein as a SHetA2-binding protein was supported by the
identification of mortalin in two different approaches: QStar
Fig. 3 SHetA2 disrupts mortalin binding to client proteins p66shc and
p53. a . Protein extracts from cultures of the A2780 and SK-OV-3 human
ovarian cancer cell lines that were either untreated (0), treated with 10 μM
SHetA2 for 4 hrs (4) or treated with the same volume of DMSO solvent
used to administer the SHetA2 for 4 hrs (4c) were incubated with an anti-
p66shc antibody overnight. The next day, antibody/protein complexes
were immunoprecipated with protein G microspheres and non-specific
binding was washed away with a Tris buffer containing NP-40 detergent.
The microspheres were boiled to remove the antibody and the samples
were electrophoresed into an SDS-gel and transferred to a Western blot
membrane which was probed with an antibody to mortalin to detect co-
immunoprecipitation and with an antibody to p66shc to detect input. b
The experiment was performed as for A, except that the immunoprecip-
itation antibody used was against mortalin and the Western blot antibody
used recognized p53. c , The experiment was performed as for A, except
that the immunoprecipitation antibody use was against p53 and the
Western blot antibody used recognized mortalin. d Western blot of
protein extracts from A2780 and SK-OV-3 cells treated with 10 μM
SHetA2 for the number of hours indicated at the bottom of the gel or
treated with the same volume of DMS0 solvent for 24 hrs (24c) or 36 hrs
(36c). The blots were stripped and re-probed with an antibody that
recognizes GAPDH as a protein loading control. These results are repre-
sentative of at least three separate experiments. IP = immunoprecipitating
antibody, IB = Immunoblotting antibody
420 Invest New Drugs (2014) 32:412–423
analysis of excised SDS-Gel bands and Orbitrap analysis of
aliquots of the whole microsphere eluents. Although QStar
analysis could not detect proteins in SDS-gel bands that were
too low for visualization by Coomassie blue staining, the
higher level of a non-specific unconjugated microsphere band
present when the experiment was scaled up to a Coomassie
blue-detectable level did not interfere with the ability of
mortalin to be identified as being differentially present in the
specific over the non-specific bands. Biological validation of
mortalin was demonstrated by SHetA2 interference with
mortalin binding to client proteins in human ovarian cancer
cell lines.
Inhibition of mortalin is a likely mechanism of the
SHetA2 effects on mitochondria and apoptosis in cancer
cells. Within 30 min of treating cancer cells, SHetA2
induces mitochondrial swelling and loss of mitochondrial
membrane potential, leading to release of cytochrome c,
generation of reactive oxygen species (ROS) and activa-
tion of the intrinsic apoptosis pathway [7, 13, 15, 16, 18,
25, 26]. Although mortalin can be found in the endoplas-
mic reticulum (ER), cytoplasmic vesicles and cytosol, the
majority of the protein present in the cell is located within
mitochondria [24]. Maintenance of mitochondrial mem-
brane potential needed for electron transport chain function
and ATP generation is dependent on mortalin interaction
with a protein called p66shc [27]. Release of p66shc from
mortalin has been shown to cause opening of mitochon-
drial pores, release of cytochrome c and ROS generation
[28]. Overexpression of mortalin can reduce ROS and
protect against ischemic injury in vitro and in vivo [29].
Thus, we hypothesize that release of p66shc from mortalin
repression mediates the mechanism by which SHetA2
induces intrinsic apoptosis. Current experiments are testing
the validity of this hypothesis. Many of the other proteins
identified in the two mass spectrometry approaches are
known to be localized to the mitochondria and involved
in metabolism. The fact that such proteins were identified
in both approaches suggests that they may have attached
indirectly to the magnetic microspheres through their af-
finity to mortalin attached to SHetA2.
SHetA2 disruption of mortalin binding to p53 is hypothe-
sized to contribute to the mechanism by which SHetA2 reg-
ulates transcription factors and apoptosis. SHetA2 induces
expression of the CHOP protein leading to enhancement of
the death receptor extrinsic apoptosis pathway [10, 11, 30].
Mortalin binds to and sequesters p53 from translocating to the
nucleus where it acts as a transcription factor to induce mul-
tiple genes that mediate apoptosis [31–33]. One of these p53-
induced transcription factors is the SHetA2-induced CHOP
[34, 35]. CHOP expression could also be altered as a result of
indirect effects of SHetA2 releasing p66shc, thereby allowing
it to interact with signal transducer and activator of transcrip-
tion 3 (STAT3) and Forkhead Box O3A (FOXO3) [36–40],
both of which regulate CHOP expression [41, 42]. Thus, we
hypothesize that SHetA2-induced release of p53 from
mortalin repression could augment SHetA2 mediated apopto-
sis. The ability of SHetA2 to induce apoptosis in p53 null cell
lines, such as SK-OV-3, suggests that SHetA2-induced release
of p53 from mortalin repression can augment but is not
required for SHetA2 apoptosis. The observation that mortalin
binds and inhibits p53 induction of apoptosis in stressed cells,
but not in weakly stressed or unstressed cells, could explain
the differential induction of apoptosis by SHetA2 in cancer
over normal cells [43].
Mortalin and SHetA2 also conflictingly regulate the Bcl-2
family of proteins. Upon activation, the pro-apoptotic Bax
protein of this family undergoes a conformational change
and migrates to the mitochondria where it forms a pore that
allows release of cytochrome c and other pro-apoptotic fac-
tors. The anti-apoptotic Bcl-2 protein binds to Bax and pre-
vents this pore formation. The ratio of Bax to Bcl-2 has been
shown to be a key determinant that can drive the initiation of
apoptosis. SHetA2 reduces the expression of Bcl-2, but not
Bax in cancer cells in vitro [7, 13, 26] and tumors in vivo[9]
leading to induction of the intrinsic apoptosis pathway, while
mortalin can prevent reduction of Bcl-2 and conformational
changes in Bax leading to inhibition of the intrinsic apoptosis
pathway [44–46].
Conclusions
SHetA2 binding proteins, such as mortalin, can be identified
by SHetA2-affinity chromatography combined with mass
spectroscopic analysis leading to testable hypotheses regard-
ing the SHetA2 molecular mechanism of action. SHetA2
interferes with mortalin binding to client proteins in ovarian
cancer cells. Inhibition of mortalin interaction with client
proteins represents a logical mechanism for SHetA2-induced
apoptosis, a theory that will be tested in future studies.
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